Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
General Information of Drug (ID: DR4680) | ||||||
---|---|---|---|---|---|---|
Drug Name |
Aprocitentan
|
|||||
Synonyms |
ACT-132577; UNII-MZI81HV01P; 1103522-45-7; Despropyl Macitentan; MZI81HV01P; CHEMBL2165326; CHEBI:76609; Macitentan metabolite; ACT 132577; SCHEMBL3646065; ZINC95553608; BDBM50395672; AKOS028114466; CS-2687; HY-15895; BC600808; 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric diamide
|
|||||
Indication | Hypertension [ICD11: BA00-BA04] | Phase 2 | [1] | |||
Structure | ||||||
3D MOL | 2D MOL | |||||
Pharmaceutical Properties | Molecular Weight | 546.2 | Topological Polar Surface Area | 151 | ||
Heavy Atom Count | 29 | Rotatable Bond Count | 8 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 10 | |||
Cross-matching ID |
|
|||||
The Predicted Metabolic Roadmap of This Drug | |||||
---|---|---|---|---|---|
The Full List of Predicted Drug Metabolites (PDM) of This Drug | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
References | ||||||
---|---|---|---|---|---|---|
1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.